PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for breast, ovarian, fallopian, primary peritoneal, prostate and pancreatic cancer. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.